Nigeria has received an initial shipment of 11,520 doses of Lenacapavir, a new injectable drug aimed at preventing HIV, delivered by the Global Fund. The handover occurred at the Federal Central Medical Stores in Oshodi, Lagos, where health officials emphasized the significance of this donation in bolstering HIV prevention strategies across the country.

Lenacapavir is a long-acting antiretroviral medication that is administered twice a year, making it a pivotal addition to the spectrum of HIV prevention methods available in Nigeria. The World Health Organisation endorses this innovative pre-exposure prophylaxis (PrEP) injection, which offers individuals a more flexible option in choosing their preferred HIV prevention method. This introduction could potentially reshape the landscape of HIV prevention and encourage more people at risk to seek preventative measures.

The head of Procurement and Supply Chain Management at the National AIDS, Viral Hepatitis, and STIs Control Programme, Mohammed Patiko, has noted that the arrival of Lenacapavir signifies a notable advancement in Nigeria's fight against HIV. The drug is part of a broader combination prevention strategy that aims to significantly lower HIV transmission rates, thus improving public health outcomes and aligning with the country's commitment to combating the HIV epidemic effectively.